U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07475026) titled 'A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence' on March 05.
Brief Summary: This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Intervention:
DRUG: Tislelizumab
Tislelizumab, 200mg, IV, q3w. Treatment will be given in 3-week cycles for a total of 2 cycles.
DRUG: Lenvatinib
Lenvatinib, 8mg for BW=60kg, PO, qd. Treatment will ...